← back to search

Stefanie Schreiber

University of California, Berkeley · US
Area of research
Neurology · Genetics
Research interest
Research focused on Amyotrophic lateral sclerosis and Cerebral amyloid angiopathy, with related work in Median nerve, Forearm, Myasthenia gravis. Notable publications include 'The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study', 'Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease', and 'Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients'.
h-index
citations
1,774
works
22
NIH funding
primary concept
email

Recent publications

Diagnosis and management of cerebral amyloid angiopathy: a scientific statement from the International CAA Association and the World Stroke Organization
International Journal of Stroke 2025cited by 13position: middledoi
Perivascular space enlargement accelerates in ageing and Alzheimer’s disease pathology: evidence from a three-year longitudinal multicentre study
Alzheimer s Research & Therapy 2024cited by 32position: middledoi
<i>MedShapeNet</i> – a large-scale dataset of 3D medical shapes for computer vision
Biomedizinische Technik/Biomedical Engineering 2024cited by 31position: middledoi
Different inflammatory signatures based on CSF biomarkers relate to preserved or diminished brain structure and cognition
Molecular Psychiatry 2024cited by 26position: middledoi
Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohort
Journal of Neurology 2024cited by 16position: middledoi
Inferior Frontal Sulcal Hyperintensities on Brain MRI Are Associated with Amyloid Positivity beyond Age—Results from the Multicentre Observational DELCODE Study
Diagnostics 2024cited by 4position: middledoi
Multimodal layer modelling reveals <i>in vivo</i> pathology in amyotrophic lateral sclerosis
Brain 2023cited by 27position: middledoi
Arterial hypertension and β-amyloid accumulation have spatially overlapping effects on posterior white matter hyperintensity volume: a cross-sectional study
Alzheimer s Research & Therapy 2023cited by 23position: middledoi
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study
The Lancet Neurology 2022cited by 635position: middledoi
Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients
Journal of Neuroinflammation 2022cited by 124position: middledoi
Eculizumab versus rituximab in generalised myasthenia gravis
Journal of Neurology Neurosurgery & Psychiatry 2022cited by 42position: middledoi
Advancing diagnostic criteria for sporadic cerebral amyloid angiopathy: Study protocol for a multicenter MRI-pathology validation of Boston criteria v2.0
International Journal of Stroke 2019cited by 53position: middledoi
Toward <i>in vivo</i> determination of peripheral nervous system immune activity in amyotrophic lateral sclerosis
Muscle & Nerve 2019cited by 33position: firstdoi
Quantitative Susceptibility MRI to Detect Brain Iron in Amyotrophic Lateral Sclerosis
Radiology 2018cited by 88position: middledoi
Significance of CSF NfL and tau in ALS
Journal of Neurology 2018cited by 68position: firstdoi
CSF-Progranulin and Neurofilament Light Chain Levels in Patients With Radiologically Isolated Syndrome—Sign of Inflammation
Frontiers in Neurology 2018cited by 25position: middledoi
Structural and diffusion imaging versus clinical assessment to monitor amyotrophic lateral sclerosis
NeuroImage Clinical 2016cited by 59position: middledoi
Quantifying disease progression in amyotrophic lateral sclerosis using peripheral nerve sonography
Muscle & Nerve 2016cited by 46position: firstdoi
Peripheral nerve ultrasound in amyotrophic lateral sclerosis phenotypes
Muscle & Nerve 2014cited by 66position: firstdoi
Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease
Journal of Crohn s and Colitis 2012cited by 188position: firstdoi
Mitofusin 2 mutations affect mitochondrial function by mitochondrial DNA depletion
Acta Neuropathologica 2012cited by 90position: middledoi
Sonography of the median nerve in CMT1A, CMT2A, CMTX, and HNPP
Muscle & Nerve 2012cited by 85position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Stefan Vielhaber · Medizinische Hochschule Hannover12 papers (2012–2023)Reinhard Dengler · National University of Singapore8 papers (2012–2019)Susanne Petri · SMART Reading7 papers (2014–2023)Peter J. Nestor · Mater Health Services6 papers (2014–2019)Katja Kollewe · Medizinische Hochschule Hannover6 papers (2012–2018)Judith Machts · Medizinische Hochschule Hannover5 papers (2014–2018) · 5 papers (2012–2019)Hans‐Jochen Heinze · Medizinische Hochschule Hannover4 papers (2014–2018)Susanne Abdulla · Wellcome Centre for Human Neuroimaging4 papers (2014–2018) · 4 papers (2012–2019)Siegfried Kropf · Medizinische Hochschule Hannover3 papers (2012–2016) · 3 papers (2016–2018)Marc Pawlitzki · Düsseldorf University Hospital3 papers (2018–2022)David J. Werring · Temple College2 papers (2019–2025)Wolfram S. Kunz · University of Tübingen2 papers (2012–2012)Benjamin Berger · University of Freiburg2 papers (2022–2022) · 2 papers (2012–2014)Daniel Bittner · Thomas Jefferson University2 papers (2018–2018)Andreas Charidimou · Université de Tours2 papers (2019–2025) · 2 papers (2022–2022)